This company listing is no longer active
This company may still be operating, however this listing is no longer active. Find out why through their latest events.
C6O Aktienübersicht
Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Clovis Oncology, Inc. Wettbewerber
Preisentwicklung & Leistung
| Historical stock prices | |
|---|---|
| Current Share Price | €0.023 |
| 52 Week High | €2.46 |
| 52 Week Low | €0.01 |
| Beta | 0.66 |
| 1 Month Change | 130.00% |
| 3 Month Change | -16.06% |
| 1 Year Change | -99.07% |
| 3 Year Change | -99.60% |
| 5 Year Change | -99.94% |
| Change since IPO | -99.86% |
Aktuelle Nachrichten und Updates
Recent updates
Aktionärsrenditen
| C6O | DE Biotechs | DE Markt | |
|---|---|---|---|
| 7D | 53.3% | -2.7% | -3.1% |
| 1Y | -99.1% | -24.2% | -0.5% |
Rendite im Vergleich zur Industrie: C6O underperformed the German Biotechs industry which returned -6.5% over the past year.
Rendite vs. Markt: C6O underperformed the German Market which returned 7.1% over the past year.
Preisvolatilität
| C6O volatility | |
|---|---|
| C6O Average Weekly Movement | 104.6% |
| Biotechs Industry Average Movement | 5.3% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 10.2% |
| 10% least volatile stocks in DE Market | 2.6% |
Stabiler Aktienkurs: C6O's share price has been volatile over the past 3 months.
Volatilität im Zeitverlauf: C6O's weekly volatility has increased from 91% to 105% over the past year.
Über das Unternehmen
| Gegründet | Mitarbeiter | CEO | Website |
|---|---|---|---|
| 2009 | 413 | Patrick Mahaffy | www.clovisoncology.com |
Clovis Oncology, Inc.'s Grundlagenzusammenfassung
| C6O grundlegende Statistiken | |
|---|---|
| Marktanteil | €2.18m |
| Gewinn(TTM) | -€226.19m |
| Umsatz(TTM) | €119.44m |
0.0x
Kurs-Umsatz-Verhältnis0.0x
Kurs-Gewinn-VerhältnisIst C6O zu teuer?
Siehe Fair Value und BewertungsanalyseErträge & Einnahmen
| C6O Gewinn- und Verlustrechnung (TTM) | |
|---|---|
| Einnahmen | US$133.02m |
| Kosten der Einnahmen | US$31.59m |
| Bruttogewinn | US$101.43m |
| Sonstige Ausgaben | US$353.33m |
| Umsatz | -US$251.91m |
Zuletzt gemeldete Gewinne
Sep 30, 2022
Datum des nächsten Gewinnberichts
k.A.
| Gewinn per Aktie (EPS) | -1.73 |
| Bruttomarge | 76.25% |
| Nettogewinnspanne | -189.37% |
| Schulden/Eigenkapital-Verhältnis | -158.0% |
Wie hat sich C6O auf lange Sicht entwickelt?
Historische Performance und Vergleiche